Tridukard of MV таб 35 mg No. 30

General characteristics. Structure:

One tablet with the modified release, film coated, contains active agent of a trimetazidin of dihydrochloride 35 mg.
Excipients: a gipromelloza (метоцель K 4M Premium EP) – 54 mg; cellulose microcrystallic – 118 mg; silicon dioxide colloid (aerosil) – 1 mg; magnesium stearate – 1 mg;
Structure of a cover: Gidroksipropilmetiltsellyuloz (gipromelloz) – 4,628 mg; talc – 0,357 mg; titanium dioxide of-1,002 mg; a macrogoal (poly(ethylene oxide) 4000) – 1,002 mg; dye an azoruby (acid red 2C for the pharmaceutical purposes) - 0,011 mg.
Description: tablets film coated pink color, round, dvoyakovypuklye.30 tablets on 35 mg.

Pharmacological properties:

Pharmacodynamics. Trimetazidin has anti-anginal, anti-hypoxemic effect. Directly influencing cardiomyocytes and neurons of a brain, optimizes their metabolism and function. The cytoprotective effect is caused by increase in energy potential, activation of oxidizing decarboxylation and rationalization of consumption of oxygen (strengthening of aerobic glycolysis and blockade of oxidation of fatty acids). Maintains contractility of a myocardium, prevents decrease in intracellular content of ATP and phosphocreatinine. In the conditions of acidosis normalizes functioning of ion channels, interferes with accumulation of calcium and sodium in cardiomyocytes, normalizes the intracellular maintenance of potassium ions. Reduces the intracellular acidosis and concentration of phosphates caused by ischemia of a myocardium and reperfusion. Interferes with the damaging action of free radicals, keeps integrity of cellular membranes, prevents activation of neutrophils in an ischemia zone, increases duration of electric potential, reduces a kreatinfosfokinaza exit from cells and expressiveness of ischemic injuries of a myocardium.
At stenocardia reduces the frequency of attacks (consumption of nitrates decreases), in 2 weeks of treatment tolerance to an exercise stress increases, differences of arterial pressure decrease. Improves hearing and results of vestibular tests at patients, reduces dizziness and a sonitus.
At vascular pathology of eyes recovers functional activity of a retina of an eye.

Pharmacokinetics. After administration of drug inside триметазидин it is quickly and almost completely absorbed from digestive tract. Bioavailability - 90%. Time of achievement of the maximum concentration in a blood plasma - 2 hours. The maximum concentration after a single dose of 35 mg of a trimetazidin - about 55 ng/ml. Easily passes through gistogematichesky barriers. The elimination half-life (T1/2) makes 4,5-5 hours. Communication with proteins of plasma - 16%. It is brought out of an organism by kidneys (about 60% - in not changed look).

Indications to use:

- An ischemic disease of a serdtsa:profilaktik of attacks of stenocardia (in complex therapy);
- Chorioretinal vascular disorders;
- Dizziness of a vascular origin;
- Cochleovestibular disturbances of the ischemic nature (sonitus, hearing disorder).

Route of administration and doses:

Inside, during food. The recommended dosing mode 2 tablets (70 mg) a day, in 2 receptions. A course of treatment according to the recommendation of the doctor.

Features of use:

Drug is not intended for stopping of attacks of stenocardia!
In case of development of an attack of stenocardia it is necessary to reconsider and adapt treatment (medicinal therapy or carrying out revascularization).
Use of drug does not influence ability to driving and performance of work, mental and physical reactions demanding high speed.

Side effects:

Allergic reactions (skin itch). Seldom from digestive tract: gastralgia, nausea, vomiting; headache, feeling of strong heartbeat.

Contraindications:

- Hypersensitivity to any component of drug;
- A renal failure (the clearance of creatinine is lower than 15 ml/min.);
- The expressed abnormal liver functions;
- Pregnancy;
- Breastfeeding period;
- Age up to 18 years (efficiency and safety are not established).

Overdose:

Now about cases of overdose of drug it was not reported.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C. To store in the place, unavailable to children. Period of validity: 3 years. Not to apply after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Tablets with the modified release, film coated, 35 mg.
On 10 or 30 tablets in a blister strip packaging.
On 30, 60, 90, 120, 180, 300 in bank polymeric or in a bottle polymeric.
Each can or bottle, 3, 6 blister strip packagings on 10 tablets or
1, 2, 3, 4, 6, 10 blister strip packagings on 30 tablets together with the application instruction place in a pack from a cardboard.